BridgeBio Pharma, Inc. Accretion Expense
BridgeBio Pharma, Inc. (BBIO) reported Accretion Expense of $53.11 million for the 6-month period ending 2025-06-30, per its 10-Q filed 2025-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2025-08-05
- BridgeBio Pharma, Inc. accretion expense for the quarter ending 2025-06-30 was $27.46M, a 1546.58% increase year-over-year.
- BridgeBio Pharma, Inc. accretion expense for the quarter ending 2025-03-31 was $25.64M, a 1172.51% increase year-over-year.
- BridgeBio Pharma, Inc. accretion expense for the quarter ending 2024-12-31 was $10.36M, a 374.76% increase year-over-year.
- BridgeBio Pharma, Inc. accretion expense for the quarter ending 2024-09-30 was $1.72M, a 19.96% decline year-over-year.
- BridgeBio Pharma, Inc. accretion expense for fiscal 2024 was $15.76M, a 76.97% increase from fiscal 2023.
- BridgeBio Pharma, Inc. accretion expense for fiscal 2023 was $8.91M, a 3.93% increase from fiscal 2022.
- BridgeBio Pharma, Inc. accretion expense for fiscal 2022 was $8.57M, a 47.89% increase from fiscal 2021.
- BridgeBio Pharma, Inc. accretion expense for fiscal 2021 was $5.79M, a 67.33% decline from fiscal 2020.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2025-06-30 | $27.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $53.11M 10-Q · filed 2025-08-05 | $63.47M derived: sum of 3 quarters · filed 2025-08-05 | $65.19M derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | $25.64M 10-Q · filed 2025-04-29 | $36.01M derived: sum of 2 quarters · filed 2025-04-29 | $37.72M derived: sum of 3 quarters · filed 2025-04-29 | $39.39M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-12-31 | $10.36M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $12.08M derived: sum of 2 quarters · filed 2025-02-20 | $13.75M derived: sum of 3 quarters · filed 2025-08-05 | $15.76M 10-K · filed 2025-02-20 |
| 2024-09-30 | $1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $3.38M derived: sum of 2 quarters · filed 2025-08-05 | $5.40M 10-Q · filed 2024-11-12 | $7.58M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-06-30 | $1.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $3.68M 10-Q · filed 2025-08-05 | $5.87M derived: sum of 3 quarters · filed 2025-08-05 | $8.01M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $2.02M 10-Q · filed 2025-04-29 | $4.20M derived: sum of 2 quarters · filed 2025-04-29 | $6.34M derived: sum of 3 quarters · filed 2025-04-29 | $8.58M derived: sum of 4 quarters · filed 2025-04-29 |
| 2023-12-31 | $2.18M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $4.33M derived: sum of 2 quarters · filed 2025-02-20 | $6.57M derived: sum of 3 quarters · filed 2025-02-20 | $8.91M 10-K · filed 2025-02-20 |
| 2023-09-30 | $2.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $4.39M derived: sum of 2 quarters · filed 2024-11-12 | $6.72M 10-Q · filed 2024-11-12 | $8.82M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $2.24M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $4.58M 10-Q · filed 2024-08-01 | $6.68M derived: sum of 3 quarters · filed 2025-02-20 | $8.77M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $2.34M 10-Q · filed 2024-05-02 | $4.44M derived: sum of 2 quarters · filed 2025-02-20 | $6.53M derived: sum of 3 quarters · filed 2025-02-20 | $8.43M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $2.10M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $4.19M derived: sum of 2 quarters · filed 2025-02-20 | $6.09M derived: sum of 3 quarters · filed 2025-02-20 | $8.57M 10-K · filed 2025-02-20 |
| 2022-09-30 | $2.09M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $3.99M derived: sum of 2 quarters · filed 2023-11-02 | $6.47M 10-Q · filed 2023-11-02 | $8.22M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $1.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $4.38M 10-Q · filed 2023-08-03 | $6.13M derived: sum of 3 quarters · filed 2024-02-22 | $7.53M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $2.48M 10-Q · filed 2023-05-04 | $4.24M derived: sum of 2 quarters · filed 2024-02-22 | $5.63M derived: sum of 3 quarters · filed 2024-02-22 | $7.03M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $3.14M derived: sum of 2 quarters · filed 2024-02-22 | $4.55M derived: sum of 3 quarters · filed 2024-02-22 | $5.79M 10-K · filed 2024-02-22 |
| 2021-09-30 | $1.39M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $2.79M derived: sum of 2 quarters · filed 2022-11-03 | $4.04M 10-Q · filed 2022-11-03 | $9.46M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $2.65M 10-Q · filed 2022-08-04 | $8.07M derived: sum of 3 quarters · filed 2023-02-23 | $13.41M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $1.25M 10-Q · filed 2022-05-05 | $6.67M derived: sum of 2 quarters · filed 2023-02-23 | $12.01M derived: sum of 3 quarters · filed 2023-02-23 | $17.23M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $5.42M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $10.76M derived: sum of 2 quarters · filed 2023-02-23 | $15.98M derived: sum of 3 quarters · filed 2023-02-23 | $17.74M 10-K · filed 2023-02-23 |
| 2020-09-30 | $5.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | $10.55M derived: sum of 2 quarters · filed 2021-11-04 | $12.31M 10-Q · filed 2021-11-04 | $13.10M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $5.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | $6.98M 10-Q · filed 2021-08-05 | $7.77M derived: sum of 3 quarters · filed 2022-02-25 | $7.79M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $1.76M 10-Q · filed 2021-05-06 | $2.55M derived: sum of 2 quarters · filed 2022-02-25 | $2.57M derived: sum of 3 quarters · filed 2022-02-25 | $2.92M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $787.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $807.00K derived: sum of 2 quarters · filed 2022-02-25 | $1.16M derived: sum of 3 quarters · filed 2022-02-25 | $1.51M 10-K · filed 2022-02-25 |
| 2019-09-30 | $20.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $368.00K derived: sum of 2 quarters · filed 2020-11-05 | $722.00K 10-Q · filed 2020-11-05 | $964.00K derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $348.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $702.00K 10-Q · filed 2020-08-11 | $944.00K derived: sum of 3 quarters · filed 2021-02-25 | |
| 2019-03-31 | $354.00K 10-Q · filed 2020-05-14 | $596.00K derived: sum of 2 quarters · filed 2021-02-25 | ||
| 2018-12-31 | $242.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $783.00K 10-K · filed 2021-02-25 | ||
| 2018-09-30 | $541.00K 10-Q · filed 2019-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |